EGFR – Non-small cell lung cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Lipodystrophy Syndromes are a
heterogeneous group of rare metabolic disorders of diverse etiology
characterized by variable loss of body fat or selective deficiency of adipose
tissue in the absence of nutritional deprivation or catabolic state. The
partial or complete loss of body fat (lipoatrophy) may occur with a
pathological accumulation of fat in other distinct body regions. Loss of fatty
tissue frequently decreases leptin levels, which interferes with hunger-satiety
signals and often leads to hyperphagia. Surplus calories are kept as fat in the
liver and muscle tissue, resulting in various metabolic manifestations. The
extent of adipose loss usually determines the severity of the associated
clinical and metabolic manifestations. Expansion of spared adipose stores in
partial lipodystrophies is one likely mechanism that leads to clinical and
metabolic manifestations. It may affect nearly the entire body (generalized),
only certain body regions (partial), or small areas under the skin (localized).
- The prevalence of cases of Lipodystrophy Syndromes varies
from 3.6 to 4.2 in every 1 MN population in the USA.
Thelansis’s “EGFR – Non-small cell
lung cancer Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential EGFR
– Non-small cell lung cancer treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of EGFR – Non-small cell lung cancer across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
EGFR – Non-small cell lung cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment